Lakefront Biotherapeutics shares rise amid rebranding and share buybacks

Shares of Lakefront Biotherapeutics NV rose 7.36% to €28.30 on the Euronext Amsterdam exchange following a period of volatility. The company, formerly known as Galapagos NV, is undergoing a strategic overhaul and rebranding process.

As part of its ongoing financial activities, Lakefront Biotherapeutics announced it repurchased 108,679 of its own ordinary shares between September 14 and September 18, 2026. The repurchases were conducted through an independent financial intermediary at an average price of €24.00. As of September 18, 2026, the company holds 1,527,534 of its own shares.

Headquartered in Mechelen, Belgium, the biotechnology firm focuses on oncology and immunology. The company’s recent transition included the appointment of Henry Gosebruch as executive director and the replacement of former Galapagos stock options with new Lakefront Biotherapeutics options.